Achieve Life Sciences IncNASDAQ:ACHV
- LAST PRICE4.5100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots4.2800/ 7
- Ask / Lots4.6600/ 50
- Open / Previous Close--- / 4.5100
- Day Range---
- 52 Week Range
- Volume40
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACHV |
|---|---|---|
| 09:32 ET | 546 | 4.32 |
| 09:39 ET | 100 | 4.31 |
| 09:44 ET | 125 | 4.37 |
| 09:48 ET | 1010 | 4.368 |
| 09:50 ET | 325 | 4.37 |
| 09:53 ET | 200 | 4.35 |
| 09:57 ET | 100 | 4.355 |
| 10:18 ET | 100 | 4.37 |
| 10:29 ET | 200 | 4.35 |
| 10:33 ET | 3775 | 4.4 |
| 10:36 ET | 100 | 4.425 |
| 10:42 ET | 500 | 4.435 |
| 10:45 ET | 2000 | 4.419 |
| 10:49 ET | 300 | 4.44 |
| 10:51 ET | 783 | 4.445 |
| 10:54 ET | 100 | 4.445 |
| 10:56 ET | 1211 | 4.445 |
| 10:58 ET | 1100 | 4.4665 |
| 11:00 ET | 100 | 4.45 |
| 11:05 ET | 184 | 4.45 |
| 11:07 ET | 100 | 4.45 |
| 11:14 ET | 3400 | 4.445 |
| 11:21 ET | 100 | 4.445 |
| 11:23 ET | 780 | 4.445 |
| 11:34 ET | 2000 | 4.4498 |
| 11:43 ET | 1115 | 4.45 |
| 11:45 ET | 2000 | 4.46 |
| 11:50 ET | 200 | 4.46 |
| 11:56 ET | 9384 | 4.48 |
| 11:59 ET | 967 | 4.53 |
| 12:01 ET | 1284 | 4.54 |
| 12:06 ET | 4507 | 4.5001 |
| 12:08 ET | 1600 | 4.52 |
| 12:19 ET | 700 | 4.5 |
| 12:28 ET | 802 | 4.5 |
| 12:37 ET | 1285 | 4.5 |
| 12:44 ET | 288 | 4.5078 |
| 12:46 ET | 400 | 4.51 |
| 12:51 ET | 100 | 4.495 |
| 12:55 ET | 400 | 4.51 |
| 12:57 ET | 500 | 4.504 |
| 01:06 ET | 600 | 4.52 |
| 01:09 ET | 922 | 4.51 |
| 01:15 ET | 200 | 4.51 |
| 01:22 ET | 2063 | 4.5 |
| 01:26 ET | 105 | 4.49 |
| 01:29 ET | 220 | 4.4957 |
| 01:31 ET | 596 | 4.49 |
| 01:38 ET | 100 | 4.5 |
| 01:40 ET | 121 | 4.5 |
| 01:42 ET | 2466 | 4.51 |
| 01:49 ET | 400 | 4.51 |
| 01:51 ET | 300 | 4.49 |
| 01:54 ET | 204 | 4.49 |
| 01:56 ET | 1430 | 4.5 |
| 02:00 ET | 550 | 4.5 |
| 02:14 ET | 100 | 4.5 |
| 02:18 ET | 100 | 4.495 |
| 02:20 ET | 175 | 4.499 |
| 02:21 ET | 100 | 4.495 |
| 02:23 ET | 100 | 4.495 |
| 02:25 ET | 1066 | 4.47 |
| 02:27 ET | 500 | 4.4872 |
| 02:30 ET | 106 | 4.475 |
| 02:45 ET | 800 | 4.48 |
| 02:52 ET | 680 | 4.49 |
| 02:54 ET | 2291 | 4.48 |
| 02:57 ET | 438 | 4.495 |
| 03:06 ET | 1580 | 4.485 |
| 03:12 ET | 100 | 4.49 |
| 03:14 ET | 1500 | 4.49 |
| 03:15 ET | 900 | 4.47 |
| 03:28 ET | 100 | 4.485 |
| 03:30 ET | 1137 | 4.47 |
| 03:35 ET | 400 | 4.5 |
| 03:39 ET | 100 | 4.49 |
| 03:42 ET | 100 | 4.5 |
| 03:46 ET | 1100 | 4.5 |
| 03:50 ET | 100 | 4.5 |
| 03:51 ET | 800 | 4.51 |
| 03:53 ET | 3816 | 4.515 |
| 03:57 ET | 2268 | 4.52 |
| 04:00 ET | 4879 | 4.51 |
Nov 14, 2024
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences, from 8:30AM ET on Thursday Nov 14, 2024 by Dow Jones
8:30AM ET on Thursday Nov 14, 2024 by Dow JonesDJ Achieve Life Sciences Initiated at Buy by Rodman & Renshaw, from 7:13AM ET on Thursday Nov 14, 2024 by Dow Jones
7:13AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 7, 2024
Achieve Life Sciences Reports Financial Results for Third Quarter 2024 and Provides Corporate Update, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
4:05PM ET on Thursday Nov 07, 2024 by Dow Jones*DJ Achieve Life Sciences 3Q Loss/Shr 36c >ACHV, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Achieve Life Sciences Inc | 147.3M | -4.0x | --- |
PepGen Inc | 143.7M | -1.5x | --- |
Black Diamond Therapeutics Inc | 143.7M | -1.8x | --- |
Acumen Pharmaceuticals Inc | 142.4M | -1.7x | --- |
Atossa Therapeutics Inc | 153.5M | -6.0x | --- |
Cytodyn Inc | 140.3M | -4.9x | --- |
Company Information
Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over the counter (OTC) products.
Contact Information
- Headquarters
- 22722 29TH DR. SE, SUITE 100SEATTLE, WA, United States 98021
- Phone
- 425-686-1500
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board
- Thomas King
- President, Director, Chief Medical Officer
- Cindy Jacobs
- Chief Executive Officer, Principal Financial Officer, Director
- Richard Stewart
- Principal Accounting Officer, Senior Director, Accounting Operations
- Jerry Wan
- Independent Director
- Stuart Duty
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $147.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 34.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.60 |
EPS | $-1.13 |
Book Value | $-0.07 |
P/E Ratio | -4.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
